about
Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum ThunbCase Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryDrug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An OverviewDrug induced hepatotoxicity: data from the Serbian pharmacovigilance database.Pathologic role of stressed-induced glucocorticoids in drug-induced liver injury in mice.Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studiesA challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug?HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.S-allylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa B-dependent pathways in mice.Approach to a patient with elevated serum alkaline phosphatase.Telmisartan/hydrochlorothiazide-induced hepatotoxicity.Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.Mechanisms of drug-induced liver injury.Modulatory potentials of aqueous leaf and unripe fruit extracts of Carica papaya Linn. (Caricaceae) against carbon tetrachloride and acetaminophen-induced hepatotoxicity in ratsThiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.DILI: New Insights into Diagnosis and Management.Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic useAssessment of drug-induced liver injury in clinical practice.Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans.Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.Antibiotic induced liver injury: what about children?Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a critically appraised topic.Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI).Hepatotoxicity effect of some Iranian medicinal herbal formulation on rats.Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.Mechanisms of phenytoin-induced toxicity in freshly isolated rat hepatocytes and the protective effects of taurine and/or melatonin.Drug-induced liver injury in the Australian setting.Acute liver failure with concurrent bupropion and carbimazole therapy.Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial.Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.Idiosyncratic drug hepatotoxicity: a 2008 update.Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients.Design, synthesis, in silico and biological evaluation of novel 2-(4-(4-substituted piperazin-1-yl)benzylidene)hydrazine carboxamides.A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection.Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literatureAbundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs Related With Drug-Induced Liver Injury
P2860
Q24628066-CDD133EB-2322-4EE5-B674-450FC9654EA1Q26749054-270D07C9-C59F-4448-9D2B-74E2645FE1C9Q26767516-84B093B2-0D60-4868-A3B5-A35F866A1587Q33836130-54268A16-51BF-4DB3-9132-098653751957Q33965293-3890A120-B4DD-4796-85E8-9181EE1A9924Q34525681-1E4EBBFD-862E-498D-8570-3FBD87C58D05Q34660447-202D40C6-CBED-4E3A-AC35-B743684CE033Q35852627-C628D238-A390-471B-8C20-09D164E7C7A8Q35854837-904C7378-844C-4147-9CC2-775C752DD304Q35926418-9DB2848E-2035-46A2-B62E-2640473B59E1Q35992161-F438BC95-695A-40EC-86D1-D7D8A6D11F18Q36247086-E2DD7523-89B3-4103-896E-6F9387C21132Q36439183-CA488983-FE94-4FCB-A652-FB9EA0EC097DQ36722382-E7F56D4B-8B67-4089-BC3B-DC4F0AEAEC19Q36772955-0909130C-CBBC-4D15-A700-E283D53BF06AQ36885006-3BB5516E-1312-4693-AE97-EB3646F4495CQ36979542-C09E30AF-0754-4F0E-A311-54C5EFC491AAQ37114105-D0395E04-F323-4E4A-A29B-86356BAC1445Q37363157-ABB20F27-1B7C-463C-8196-81EA67913E49Q37711165-1B95AB52-B6E4-405B-92D8-05AC1B0C9B3FQ38144140-E72343B5-26A5-401E-8979-9FEC98CD0A45Q38649857-B9D7BBFE-9044-4C18-904C-CF3E9E892261Q39258217-629E6F11-6443-495B-830D-3A42FA3CF639Q41965179-01F36DEF-06C1-4878-9721-017A2E72A553Q42704420-ADFA1169-270F-475A-B6D3-D477BFA22B60Q42707001-7F2583EB-0EC3-42A3-A868-E223272B1434Q43424045-381BFFD3-EA38-4237-B922-EEE0B5852574Q44292364-1FF40644-5AED-4516-A86F-3D0B36DE5897Q46699066-DB7365F3-A9DE-4673-8047-F915FE31F704Q46753163-C3D9D573-9510-421E-9D71-39268BA8C185Q47375273-E06F7D30-D260-4ACB-882E-69EBB2AD725FQ47847637-0ADCE168-91EB-4C3D-9FA1-35B7F58992C7Q51712894-B4104A44-8136-431F-9733-BDFB6153F8D1Q51916542-CA48132C-C871-4573-BBC2-1A69157C5FDCQ54584930-B94204F9-5063-4C73-9F1F-2E1570E030F5Q55014958-C2674622-9DFA-4DA7-A52D-1330338D66F9Q58709126-1B6E1407-BACF-4F7E-827F-D98209CBEADEQ58711392-6220F0DC-BD18-485D-B0C7-68E0ED714C4F
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Drug-induced liver diseases.
@ast
Drug-induced liver diseases.
@en
type
label
Drug-induced liver diseases.
@ast
Drug-induced liver diseases.
@en
prefLabel
Drug-induced liver diseases.
@ast
Drug-induced liver diseases.
@en
P1476
Drug-induced liver diseases.
@en
P2093
P356
10.1016/S0168-8278(00)80417-1
P433
P577
2000-01-01T00:00:00Z